$HAIAF
Healthcare AI Acquisition Corp.

2022 Q4 Form 10-K Financial Statement

#000119312523088378 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $251.3K $1.206M
YoY Change -90.61% -55.2%
Operating Profit -$1.206M
YoY Change
Interest Expense $1.837M $3.112M
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.533M $14.00M
YoY Change -88.56% 4.43%
Pretax Income $3.119M $12.80M
YoY Change -70.94% 19.41%
Income Tax
% Of Pretax Income
Net Earnings $3.119M $12.80M
YoY Change -70.94% 19.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.14 $0.49
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $401.3K $401.3K
YoY Change -83.95% -83.95%
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets $222.8K $222.8K
YoY Change -57.6% -57.6%
Inventory
Prepaid Expenses $222.8K
Receivables
Other Receivables
Total Short-Term Assets $624.1K $624.1K
YoY Change -79.37% -79.37%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $223.0M $223.0M
YoY Change 1.42% 1.42%
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $223.0M $223.0M
YoY Change 1.31% 1.31%
TOTAL ASSETS
Total Short-Term Assets $624.1K $624.1K
Total Long-Term Assets $223.0M $223.0M
Total Assets $223.7M $223.7M
YoY Change 0.22% 0.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $28.66K $28.66K
YoY Change -97.92% -98.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $155.8K $155.8K
YoY Change -91.28% -92.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.179M $9.179M
YoY Change -53.16% -53.16%
Total Long-Term Liabilities $9.179M $9.179M
YoY Change -53.16% -53.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $155.8K $155.8K
Total Long-Term Liabilities $9.179M $9.179M
Total Liabilities $9.334M $9.334M
YoY Change -56.86% -56.86%
SHAREHOLDERS EQUITY
Retained Earnings -$8.711M
YoY Change -52.65%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.710M $214.3M
YoY Change
Total Liabilities & Shareholders Equity $223.7M $223.7M
YoY Change 0.22% 0.22%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $3.119M $12.80M
YoY Change -70.94% 19.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$63.89K -$1.852M
YoY Change -97.52% -28.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -246.8K
YoY Change -100.0% -100.11%
NET CHANGE
Cash From Operating Activities -63.89K -1.852M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 -246.8K
Net Change In Cash -63.89K -2.099M
YoY Change -102.56% -183.95%
FREE CASH FLOW
Cash From Operating Activities -$63.89K -$1.852M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Cash
Cash
401275
CY2021Q4 us-gaap Cash
Cash
2500000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
222834
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
525552
CY2022Q4 us-gaap Assets Current
AssetsCurrent
624109
CY2021Q4 us-gaap Assets Current
AssetsCurrent
3025552
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
219835
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001848861
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Registrant Name
EntityRegistrantName
Healthcare AI Acquisition Corp.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity File Number
EntityFileNumber
001-41145
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1585450
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
190 Elgin Avenue
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
George Town
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Grand Cayman
CY2022 dei Entity Address Country
EntityAddressCountry
KY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10177
CY2022 dei City Area Code
CityAreaCode
345
CY2022 dei Local Phone Number
LocalPhoneNumber
815-8548
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q3 dei Entity Public Float
EntityPublicFloat
217560000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.5
CY2022 haia Threshold Business Days For Redemption Of Public Shares
ThresholdBusinessDaysForRedemptionOfPublicShares
P10D
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
West Palm Beach, FL
CY2022Q4 haia Cash And Investments Held In Trust Account
CashAndInvestmentsHeldInTrustAccount
223048887
CY2021Q4 haia Cash And Investments Held In Trust Account
CashAndInvestmentsHeldInTrustAccount
219936490
CY2022Q4 us-gaap Assets
Assets
223672996
CY2021Q4 us-gaap Assets
Assets
223181877
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28655
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1377113
CY2021Q4 haia Promissory Note Payable To Related Party
PromissoryNotePayableToRelatedParty
246766
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
127095
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7095
CY2021Q4 haia Over Allotment Liability
OverAllotmentLiability
155881
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
155750
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1786855
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1314370
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
12048389
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
317285
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
257285
CY2022Q4 haia Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7546840
CY2021Q4 haia Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7546840
CY2022Q4 us-gaap Liabilities
Liabilities
9334245
CY2021Q4 us-gaap Liabilities
Liabilities
21639369
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
223048887
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
219936490
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8710675
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18394557
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8710136
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18393982
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223672996
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223181877
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1206054
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2692120
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1206054
us-gaap Operating Income Loss
OperatingIncomeLoss
-2692120
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10734019
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13362758
CY2022 haia Interest Income On Investments Held In Trust Account
InterestIncomeOnInvestmentsHeldInTrustAccount
-3112397
CY2022 haia Change In Fair Value Of Overallotment Liability
ChangeInFairValueOfOverallotmentLiability
-155881
haia Change In Fair Value Of Overallotment Liability
ChangeInFairValueOfOverallotmentLiability
-45383
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14002297
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13408141
CY2022 us-gaap Profit Loss
ProfitLoss
12796243
us-gaap Profit Loss
ProfitLoss
10716021
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
haia Accretion Of Ordinary Shares Subject To Possible Redemption
AccretionOfOrdinarySharesSubjectToPossibleRedemption
24822523
haia Excess Proceeds Received Over Initial Fair Value Of Private Placement Warrants
ExcessProceedsReceivedOverInitialFairValueOfPrivatePlacementWarrants
4312480
us-gaap Net Income Loss
NetIncomeLoss
10716021
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18393982
CY2022 haia Re Measurement Of Class A Ordinary Shares Subject To Possible Redemption
ReMeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption
-3112397
CY2022 us-gaap Net Income Loss
NetIncomeLoss
12796243
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8710136
CY2022 us-gaap Profit Loss
ProfitLoss
12796243
us-gaap Profit Loss
ProfitLoss
10716021
haia Formation And Operating Costs Paid By Sponsor
FormationAndOperatingCostsPaidBySponsor
25560
CY2022 haia Interest Earned On Investments Held In Trust
InterestEarnedOnInvestmentsHeldInTrust
-3112397
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10734019
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13362758
CY2022 haia Change In Overallotment Liability
ChangeInOverallotmentLiability
-155881
haia Change In Overallotment Liability
ChangeInOverallotmentLiability
-45383
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-522553
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
745387
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1348458
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
826424
CY2022 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
120000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
7095
CY2022 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
60000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1851959
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2578428
us-gaap Payments To Acquire Trust Preferred Investments
PaymentsToAcquireTrustPreferredInvestments
219936490
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-219936490
haia Proceeds From Initial Public Offering Net Of Costs And Fair Value Of Warrant
ProceedsFromInitialPublicOfferingNetOfCostsAndFairValueOfWarrant
213889958
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11124960
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
246766
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-246766
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225014918
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2098725
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2500000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
401275
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2500000
us-gaap Stock Issued1
StockIssued1
25000
CY2022 haia Accretion Of Class A Ordinary Shares Subject To Possible Redemption
AccretionOfClassAOrdinarySharesSubjectToPossibleRedemption
3112397
haia Accretion Of Class A Ordinary Shares Subject To Possible Redemption
AccretionOfClassAOrdinarySharesSubjectToPossibleRedemption
219936490
haia Deferred Underwriting Payable Charged To Additional Paid In Capital
DeferredUnderwritingPayableChargedToAdditionalPaidInCapital
7546840
haia Deferred Offering Cost Included In Accrued Offering Costs And Expenses
DeferredOfferingCostIncludedInAccruedOfferingCostsAndExpenses
820574
haia Deferred Offering Costs Paid By Related Party
DeferredOfferingCostsPaidByRelatedParty
246206
haia Initial Value Of Warrant Liability
InitialValueOfWarrantLiability
25411147
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
36
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
2500000
CY2022 haia Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account
ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount
0.80
CY2022 haia Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50
CY2022 haia Number Of Business Days To Redeem Shares Upon Completion Of Initial Business Combination
NumberOfBusinessDaysToRedeemSharesUponCompletionOfInitialBusinessCombination
two business days
CY2022Q4 us-gaap Share Price
SharePrice
10.2
CY2022Q4 haia Minimum Net Tangible Assets
MinimumNetTangibleAssets
5000001
CY2022 haia Threshold Period From Closing Of Initial Public Offering Company Is Obligated To Complete Business Combination
ThresholdPeriodFromClosingOfInitialPublicOfferingCompanyIsObligatedToCompleteBusinessCombination
P18M
CY2022 haia Minimum Net Interest To Pay Dissolution Expenses
MinimumNetInterestToPayDissolutionExpenses
100000
CY2022 haia Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2022Q4 us-gaap Share Price
SharePrice
10.2
CY2022Q4 us-gaap Share Price
SharePrice
10.2
CY2022Q4 us-gaap Cash
Cash
401275
CY2021Q4 us-gaap Cash
Cash
2500000
CY2022Q4 haia Working Capital
WorkingCapital
468359
CY2021Q4 haia Working Capital
WorkingCapital
1238697
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statement in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of <div style="display:inline;">contingent </div>assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Reclassifications </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain reclassifications have been made to the historical financial statements to conform to the current year’s presentation. Such reclassifications have no effect on net income (loss) as previously reported. </div>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q4 us-gaap Cash
Cash
401275
CY2021Q4 us-gaap Cash
Cash
2500000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022Q4 haia Cash And Investments Held In Trust Account
CashAndInvestmentsHeldInTrustAccount
223048887
CY2021Q4 haia Cash And Investments Held In Trust Account
CashAndInvestmentsHeldInTrustAccount
219936490
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 haia Accrued Interest And Penalties
AccruedInterestAndPenalties
0
CY2022 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, “Derivatives and Hedging—Contracts in Entity’s Own Equity” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessed</div> at the end of each reporting period. In accordance with ASC Topic 825 “Financial Instruments,” offering costs attributable to the issuance of the derivative warrant liabilities have been allocated based on their relative fair value of total proceeds and are recognized in the statement of operations as incurred. </div>
CY2022Q4 haia Dissolution Expense
DissolutionExpense
100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2022Q4 haia Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Stock Price Trigger
TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
12
CY2022 haia Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences
ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
P150D
CY2022 us-gaap Sponsor Fees
SponsorFees
10000
CY2022Q4 haia Accrued Sponsor Fees
AccruedSponsorFees
127095
CY2021Q4 haia Accrued Sponsor Fees
AccruedSponsorFees
7095
CY2022 haia Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
CY2021Q4 haia Cash Underwriting Discount Percentage
CashUnderwritingDiscountPercentage
0.02
CY2021Q4 haia Underwriter Cash Discount
UnderwriterCashDiscount
4312480
CY2021Q4 haia Deferred Underwriting Discount Percentage
DeferredUnderwritingDiscountPercentage
0.035
CY2021Q4 haia Deferred Underwriter Discount Amount
DeferredUnderwriterDiscountAmount
7546840
CY2022Q4 haia Percentage Of Gross Proceeds On Equity Proceeds
PercentageOfGrossProceedsOnEquityProceeds
0.60
CY2022Q4 haia Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price
ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice
1.15
CY2022Q4 haia Class Of Warrant Or Right Adjustment Of Redemption Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price One
ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPriceOne
1.80
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0

Files In Submission

Name View Source Status
0001193125-23-088378-index-headers.html Edgar Link pending
0001193125-23-088378-index.html Edgar Link pending
0001193125-23-088378.txt Edgar Link pending
0001193125-23-088378-xbrl.zip Edgar Link pending
d356043d10k.htm Edgar Link pending
d356043dex21.htm Edgar Link pending
d356043dex311.htm Edgar Link pending
d356043dex312.htm Edgar Link pending
d356043dex321.htm Edgar Link pending
d356043dex322.htm Edgar Link pending
d356043dex42.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
haia-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
haia-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
haia-20221231_lab.xml Edgar Link unprocessable
d356043d10k_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
haia-20221231_cal.xml Edgar Link unprocessable
haia-20221231_pre.xml Edgar Link unprocessable